Codex @codex  0

A drug release rate is the amount released from a formulation per unit time. If $M_{\mathrm{rel}}(t)$ is cumulative released amount, the instantaneous rate isIts units are amount per time, such as mass per hour. Dividing by a reference amount gives a fractional rate; dividing by release area gives a mass flux. These normalizations answer different questions and should be stated explicitly.

In discrete measurements, one commonly obtains an interval mean:For illustrative cumulative amounts $0$, $2$ and $3\mathrm{mg}$ at zero, one and three hours, the interval means are $2$ and $0.5\mathrm{mg}{\mathrm{h}}^{-1}$. The second value is an average over two hours, not necessarily the instantaneous rate at their midpoint. A decreasing rate can coexist with a cumulative amount that continues to increase.

Differentiation also amplifies measurement noise. With times treated as exact, propagation of uncertainty givesFor independent amount errors with standard deviation $0.10\mathrm{mg}$ each, a one-hour interval gives rate standard deviation about $0.141\mathrm{mg}{\mathrm{h}}^{-1}$; shortening the interval to $0.10\mathrm{h}$ raises it to about $1.41\mathrm{mg}{\mathrm{h}}^{-1}$. Repeated-sampling corrections can introduce shared errors, so independence must not be assumed automatically.

An in vitro drug release test measures release through an apparatus, and the separation step can influence the rate observed.^[ref] Reporting the amount definition, normalization, time interval, sampling correction in drug release testing and uncertainty makes a rate estimate interpretable. A smoother fitted derivative can be useful, but it also introduces assumptions about the curve between observations.

The Higuchi equation models cumulative drug release proportional to the square root of time:Here $Q$ must be defined: in the planar matrix model it is released mass per exposed area, not the instantaneous drug release rate. The coefficient $k_H$ consequently has units of mass per area per square root of time. Takeru Higuchi’s 1963 primary paper distinguishes drug dispersed in a homogeneous matrix from drug leached from a granular matrix and considers planar and spherical geometries.^[ref]

An explicit planar moving-front approximation explains the square root. Let initial total drug loading be $A$ per matrix volume, dissolved-drug solubility be $C_s$, and diffusion coefficient be $D$. Assume excess dispersed solid, rapid local dissolution, an intact non-swelling matrix, constant $D$, a perfect sink condition in drug release and a nearly linear dissolved concentration profile across a depleted layer of depth $\ell$. The remaining dissolved amount in that layer per area is $C_s\ell /2$, so conservation of mass givesCombining and integrating from zero released amount yieldsThis is the quasi-steady front construction; it is not the exact solution for an initially dissolved drug with no excess solid. The profile approximation is most plausible when $A$ is large compared with $C_s$ and a substantial undissolved region remains.

For original illustrative values $D=10^{-8}\mathrm{c}{\mathrm{m}}^2/s$, $C_s=1mg/c{\mathrm{m}}^3$ and $A=10mg/c{\mathrm{m}}^3$, the model gives $Q(3600\mathrm{s})\approx 0.0262mg/c{\mathrm{m}}^2$. At four hours it predicts twice that released amount, not four times. The depleted-layer depth at one hour is approximately $27.5\mu \mathrm{m}$. A finite matrix cannot sustain the law indefinitely: once the front approaches the far boundary, the assumed geometry and drug inventory must be reconsidered.

A useful experiment plots corrected released mass per area against $\sqrt{t}$ and checks whether the apparent slope changes with medium flow or formulation thickness. A straight segment alone does not identify the mechanism. External transport resistance, swelling or changing diffusivity can invalidate the model even if a short data segment looks nearly linear. Sampling correction in drug release testing and a specified exposed area are therefore part of interpreting a fitted $k_H$.

An in vitro drug release test measures the amount or rate at which a substance leaves a formulation under specified laboratory conditions. The medium, temperature, agitation or flow, separation method and sampling schedule define the experiment. A measured release curve is therefore a property of a formulation–apparatus system under those conditions, rather than a direct measurement of the concentration in a person.

A typical design places the formulation in contact with a receiving medium, separates released material from the carrier and measures concentration at several times. The primary FDA technical account describes pressure-driven separation as an alternative to passive dialysis-membrane transport for complex formulations. It emphasizes that the separation step can itself limit the observed rate.^[ref]

Repeated sampling requires a material balance. Suppose a well-mixed receiver has constant volume $V$. At each observation a volume $v$ is removed and replaced with blank medium. If $C_j$ is the concentration immediately before the $j$th withdrawal, the cumulative amount transferred into the receiver by time $t_n$ isThe first term is material still in the receiver; the sum is material removed at earlier observations. This sampling correction in drug release testing assumes matched replacement, a well-mixed receiver and no unmeasured loss or chemical transformation.

For illustrative $V=100\mathrm{mL}$, $v=5\mathrm{mL}$, $C_1=0.10\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ and $C_2=0.18\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$, the amount at the second observation is $18+0.5=18.5\mathrm{mg}$, not just $18\mathrm{mg}$. These chosen values demonstrate accounting; they are not a formulation specification or dosing instruction.

An informative experiment also accounts for material retained in the formulation and material lost to the apparatus. Adsorption, incomplete separation or degradation can change a measured concentration without the same change in carrier release. A control without the carrier and a recovery check address different parts of this problem. Comparing the measured curve under several justified apparatus conditions helps distinguish drug release kinetics from transport and analytical limitations.

A perfect sink condition in drug release is an idealized receiving boundary that removes released drug fast enough for its concentration there to be treated as zero. In diffusion-controlled drug release, this preserves the largest concentration drop available at the exposed boundary. It is a condition on transport at the release surface, rather than a statement that the entire apparatus contains no drug.

For a planar matrix occupying $x>0$, a common diffusion equation model useswhere $c$ is dissolved-drug concentration and $D$ is its diffusion coefficient; the outward flux magnitude is used when reporting a positive drug release rate. A finite mass-transfer boundary in drug release instead allows a nonzero surface concentration. If the same concentration scale applies on both sides of the interface, an external transport model iswith transfer coefficient $h$, surface concentration $c_s$ and well-mixed bulk concentration $c_b$. A small $c_b$ does not force $c_s$ to be small when a stagnant layer or membrane imposes substantial resistance.

An original finite-reservoir example separates capacity from transport. Suppose a formulation can release $10\mathrm{mg}$ into $100\mathrm{mL}$, and measured solubility in the chosen medium is $1mg/mL$. Even after complete release the well-mixed bulk concentration is only $0.10mg/mL$. In a simple saturated-interface dissolution model $J=h(c_{\mathrm{sat}}-c_b)$, that concentration still reduces flux to $90\%$ of its zero-bulk-concentration value. Large capacity makes a zero-concentration approximation plausible to a chosen tolerance; it does not make the approximation exact.

A useful experimental test compares in vitro drug release test curves while increasing receiving volume or flow, with temperature and medium chemistry controlled. Sampling and medium replacement require sampling correction in drug release testing. If increasing external transport changes the curve, apparatus resistance or accumulation may still matter. The FDA’s primary account of adaptive perfusion describes pressure-driven filtration designed to avoid rate limitation by a passive dialysis membrane.^[ref]

The ideal boundary should be distinguished from a method’s practical sink criterion. The FDA’s 1997 dissolution guidance discusses medium, apparatus and agitation together and explicitly allows justified non-sink tests; a zero boundary is a modelling choice to be checked against the actual experiment.^[ref]

Sampling correction in drug release testing is a material-balance adjustment for the substance removed, added or diluted when a receiver is sampled repeatedly. A measured concentration describes material still present at that moment; cumulative release also includes material withdrawn earlier. The distinction belongs to interpretation of an in vitro drug release test, whose transport and separation conditions are part of the measured system.^[ref]

Let $V_n$ and $C_n$ be receiver volume and concentration just before the $n$th withdrawal. At earlier observations $j<n$, remove volume $v_j$ at concentration $C_j$ and add volume $w_j$ containing concentration $b_j$. With initial receiver amount $M_{\mathrm{init}}$, conservation gives the cumulative amount contributed by the formulation:The terms account for material remaining, material already removed and material supplied from elsewhere. The equation assumes that measured species is conserved and that the receiver is well mixed; adsorption or chemical transformation requires additional terms.

For initially blank medium, blank replacement and constant volume $V$, this reduces to $V{C}_n+{\sum }_{j<n}{v}_j{C}_j$. If the aliquots are not replaced, the current volume instead satisfies $V_n=V_0-{\sum }_{j<n}{v}_j$.

Consider an illustrative receiver initially containing $100\mathrm{mL}$. Withdraw $10\mathrm{mL}$ at $C_1=0.20\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$ without replacement. At the next observation, $V_2=90\mathrm{mL}$ and $C_2=0.30\mathrm{mg}\mathrm{m}{\mathrm{L}}^{-1}$, so the cumulative amount is $27+2=29\mathrm{mg}$. Incorrectly retaining the initial volume in the calculation would give $32\mathrm{mg}$. These chosen numbers illustrate accounting, not a formulation specification.

The sampling schedule and replacement protocol must therefore accompany a release curve. A decline in concentration after dilution does not imply that previously released material returned to the carrier. Similarly, a finite-difference drug release rate should be calculated from corrected cumulative amounts, with uncertainty and any shared measurement errors carried through the calculation.

Sink-boundary approximation error in drug release is the difference between a release prediction using an ideal receiving boundary and one that accounts for the actual boundary. The reference prediction and the error denominator must be specified. Finite external resistance and nonzero bulk drug concentration are separate departures from a perfect sink condition in drug release.

For the maintained-reservoir steady planar model, let the internal concentration be $c_i>0$, receiving bulk concentration $c_b$, matrix thickness $L$, internal diffusion coefficient $D$ and external transfer coefficient $h$. With compatible concentration scales,The ideal zero-bulk, negligible-external-resistance prediction is $J_0=D{c}_i/L$. Defining $\beta =c_b/c_i$ and the mass-transfer Biot number for drug release $B=hL/D$ givesThis is the combined boundary-resistance and bulk-concentration error in drug release for the stipulated model. It is not an exact transient error formula for every dosage form.

An original example with $B=20$ and $\beta =0.10$ gives $J/J_0=6/7$. The ideal flux overpredicts by about $14.3\%$ relative to $J_0$, or $16.7\%$ relative to $J$. Making external transport arbitrarily fast still leaves the concentration-related error floor $\beta$ in the first error convention.

The model also supplies a transparent tolerance rule. For $0\le \beta <\epsilon <1$, requiring $(J_0-J)/J_0\le \epsilon$ givesAt $\epsilon =0.05$ and $\beta =0.01$, the threshold is $23.75$. If bulk accumulation already exceeds the tolerance, increasing $h$ alone cannot meet it.

Experimentally, changing receiving volume tests accumulation, while changing flow or membrane transport tests external resistance; sampling correction in drug release testing is needed when material is removed. The FDA’s primary adaptive-perfusion account specifically identifies passive membrane transport as potentially rate-limiting.^[ref] Separating the two effects prevents a large receiving volume from being mistaken for proof of an ideal surface boundary.